Cooperative Study of The Clinical Course of Sickle Cell Disease
Sponsors
Source
National Heart, Lung, and Blood Institute (NHLBI)
Brief Summary
To determine the natural history of sickle cell disease from birth to death in order to
identify those factors contributing to the morbidity and mortality of the disease.
Detailed Description
BACKGROUND:
Sickle cell anemia (Hb SS) and related hemoglobinopathies involving sickle hemoglobin (HbS)
had been recognized for many years and numerous clinical and laboratory manifestations had
been described. However, the clinical course of sickle cell disease was poorly documented.
The ability to establish concrete interrelationships among signs, symptoms and laboratory
test results was complicated by the complexity of the interaction of basic disease processes
with other health related events.
Comprehensive evaluations of the clinical status of patients were usually carried out only
during hospitalizations for 'crises' or other acute illnesses. Because of this inconsistent
nature of the doctor/patient relationships, methods of periodic recording of the patient's
status needed to be established. Further, the obtaining of comprehensive laboratory data was
necessary during periods of apparent clinical remissions as well as hospitalizations. A well
designed, statistically valid, longitudinal study could make a significant contribution to a
better understanding of sickle cell disease. Information was particularly lacking on the
clinical course starting at birth. Criteria needed to be formulated that could establish
classifications of organ involvement and severity of the disease processes. Such
classifications could ultimately be used in establishing the need for and evaluating the
efficacy of proposed therapies.
The source of the idea for the study dates back to 1971 when the Hematology Study Section
recommended in a position paper a study on the natural history of sickle cell disease. The
Hemolytic Disease Study Group of the Division of Blood Diseases and Resources developed a
detailed protocol in 1973. The National Sickle Cell Disease Advisory Committee endorsed the
idea in 1975. In April 1976, the Red Cell Working Group of the Blood Diseases and Resources
Advisory Committee recommended initiating the study. The National Heart, Lung, and Blood
Advisory Council approved the initiative in December 1976.
Phase I, the Planning Phase, began in 1977. The protocols and Manual of Operations were
developed in this phase. Phase II, the Enrollment Phase, began in March 1979 and ended in
March 1981, except for infants younger than 6 months of age, who continued to be enrolled
after March 1981. In 1983 the study was extended for an additional five years through 1988.
Beginning in 1989, as a separate initiative, the study follows selected patient groups from
the original study for an additional five years. The selected groups include the newborn
cohort and patients surviving beyond age 35.
In 1981, the NHLBI offered a special competition for the evaluation of cardiac function in
sickle cell disease patients who were enrolled in the cooperative study of sickle cell
disease. The original general study protocol required assessment of the lungs, spleen,
kidneys, eyes, and liver but not the heart. The cardiac function study objectives were: to
determine cardiac function in a cross-section of sickle cell patients participating in the
larger study; to determine the incidence, prevalence, and onset of cardiac impairment; and to
assess changes in cardiac function and correlate the observed changes with other clinical
data. A total of 300 patients had an entry cardiac evaluation in the third year of the study
(June 1, 1981 through November 30, 1981) and an exit cardiac evaluation two years later in
the fifth year of the study which was conducted at four centers.
Twelve cooperative study of sickle cell disease centers and eleven other clinical
institutions initiated the Penicillin Prophylaxis in Sickle Cell Disease (PROPS I) clinical
trial in August 1983. The objective of the trial was to determine whether the regular daily
administration of oral penicillin would reduce the incidence of documented infection due to
Streptococcus pneumoniae in children aged 3 months to 3 years with sickle cell anemia. The
trial was scheduled to end in February 1986 but was terminated eight months early, after an
average of 15 months of follow-up, when an 84 percent reduction in the incidence of infection
was observed in the penicillin group as compared to the placebo group.
DESIGN NARRATIVE:
Baseline data were collected, including demographic and past medical history and clinical and
laboratory information. Stabilized patients were re-examined every six months. Newborns and
young infants were re-examined every two to three months. Organ damage to the lungs, spleen,
kidneys, eyes, and liver was measured at specific entry and exit points to provide
longitudinal data. Data was also gathered on all acute and chronic complications related to
sickle cell disease to provide cross-sectional evaluation.
Overall Status
Completed
Start Date
1977-09-01
Completion Date
2000-12-01
Primary Completion Date
N/A
Study Type
Observational
Conditions
Eligibility
Criteria
Black males and females with sickle cell disease
Gender
All
Minimum Age
N/A
Maximum Age
25 Years
Healthy Volunteers
No
Overall Official
Last Name |
Affiliation |
Paul Levy |
University of Illinois at Chicago |
Verification Date
2004-08-01
Lastchanged Date
N/A
Firstreceived Date
N/A
Has Expanded Access
No
Condition Browse
Firstreceived Results Date
N/A
Reference
Citation
Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991 Nov 21;325(21):1476-81.
PMID
1944426
Citation
Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991 Jul 4;325(1):11-6.
PMID
1710777
Citation
Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990 Jun 7;322(23):1617-21.
PMID
2342522
Citation
Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990 Oct 1;76(7):1431-7.
PMID
2207318
Citation
Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982 Summer;4(2):197-201.
PMID
7114401
Citation
Steinberg MH, Rosenstock W, Coleman MB, Adams JG, Platica O, Cedeno M, Rieder RF, Wilson JT, Milner P, West S. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood. 1984 Jun;63(6):1353-60.
PMID
6722353
Citation
Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med. 1984 Jul 5;311(1):7-12.
PMID
6727978
Citation
Farber MD, Koshy M, Kinney TR. Cooperative Study of Sickle Cell Disease: Demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985;38(6):495-505.
PMID
4008590
Citation
Embury SH, Gholson MA, Gillette P, Rieder RF. The leftward deletion alpha-thal-2 haplotype in a black subject with hemoglobin SS. Blood. 1985 Mar;65(3):769-71.
PMID
3971048
Citation
Pearson HA, Gallagher D, Chilcote R, Sullivan E, Wilimas J, Espeland M, Ritchey AK. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics. 1985 Sep;76(3):392-7.
PMID
2412200
Citation
Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falletta JM, Lande WM, Levy PS, Verter JI, Wethers D. Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986 Oct;109(4):579-85.
PMID
3531449
Citation
Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986 Jun 19;314(25):1593-9.
PMID
3086721
Citation
Espeland M. Estimation of growth curves from longitudinal data collected at irregular time intervals. Comput Biomed Res. 1986 Dec;19(6):575-87.
PMID
3791979
Citation
Gaston M, Smith J, Gallagher D, Flournoy-Gill Z, West S, Bellevue R, Farber M, Grover R, Koshy M, Ritchey AK, et al. Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials. 1987 Dec;8(4 Suppl):131S-140S.
PMID
3440386
Citation
Steinberg MH, West MS, Gallagher D, Mentzer W. Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anemia. Blood. 1988 Mar;71(3):748-52.
PMID
3345344
Citation
Koshy M, Entsuah R, Koranda A, Kraus AP, Johnson R, Bellvue R, Flournoy-Gill Z, Levy P. Leg ulcers in patients with sickle cell disease. Blood. 1989 Sep;74(4):1403-8.
PMID
2475188
Citation
Lee PC. Consistent collimator overlaps in field matching with computer-controlled x-ray collimators. Med Dosim. 1997 Spring;22(1):59-61.
PMID
9136110
Citation
Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997 Mar 1;89(5):1787-92.
PMID
9057664
Citation
Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, Wethers DL, Bello JA, Vichinsky EP, Moser FG, Gallagher DM, DeBaun MR, Platt OS, Miller ST. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999 Mar;103(3):640-5.
PMID
10049969
Citation
Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996 Jun;97(6 Pt 1):864-70.
PMID
8657528
Citation
Moser FG, Miller ST, Bello JA, Pegelow CH, Zimmerman RA, Wang WC, Ohene-Frempong K, Schwartz A, Vichinsky EP, Gallagher D, Kinney TR. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 1996 May;17(5):965-72.
PMID
8733975
Citation
Koshy M, Weiner SJ, Miller ST, Sleeper LA, Vichinsky E, Brown AK, Khakoo Y, Kinney TR. Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. Blood. 1995 Nov 15;86(10):3676-84.
PMID
7579333
Citation
Smith JA, Espeland M, Bellevue R, Bonds D, Brown AK, Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol. 1996 Feb;87(2):199-204.
PMID
8559523
Citation
Covitz W, Espeland M, Gallagher D, Hellenbrand W, Leff S, Talner N. The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD). Chest. 1995 Nov;108(5):1214-9.
PMID
7587419
Citation
Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow CH, Vichinsky E. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995 Jul 15;86(2):776-83. Review.
PMID
7606007
Citation
Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med. 1994 Aug;148(8):796-804.
PMID
7519102
Citation
Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994 Jul 15;84(2):643-9.
PMID
7517723
Citation
Wang WC, Grover R, Gallagher D, Espeland M, Fandal A. Developmental screening in young children with sickle cell disease. Results of a cooperative study. Am J Pediatr Hematol Oncol. 1993 Feb;15(1):87-91.
PMID
7680549
Citation
West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol. 1992 Aug;45(8):893-909.
PMID
1624972
Citation
Wang WC, Gallagher DM, Pegelow CH, Wright EC, Vichinsky EP, Abboud MR, Moser FG, Adams RJ. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):335-9.
PMID
10959904
Citation
Burlew K, Telfair J, Colangelo L, Wright EC. Factors that influence adolescent adaptation to sickle cell disease. J Pediatr Psychol. 2000 Jul-Aug;25(5):287-99.
PMID
10880059
Citation
Thompson RJ Jr, Armstrong FD, Kronenberger WG, Scott D, McCabe MA, Smith B, Radcliffe J, Colangelo L, Gallagher D, Islam S, Wright E. Family functioning, neurocognitive functioning, and behavior problems in children with sickle cell disease. J Pediatr Psychol. 1999 Dec;24(6):491-8.
PMID
10608100
Citation
Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001 Sep;139(3):385-90.
PMID
11562618
Citation
Wang W, Enos L, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Zimmerman R, Armstrong FD; Cooperative Study of Sickle Cell Disease. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001 Sep;139(3):391-7.
PMID
11562619
Citation
Thompson RJ Jr, Armstrong FD, Link CL, Pegelow CH, Moser F, Wang WC. A prospective study of the relationship over time of behavior problems, intellectual functioning, and family functioning in children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr Psychol. 2003 Jan-Feb;28(1):59-65.
PMID
12490632
Citation
Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002 Apr 15;99(8):3014-8.
PMID
11929794
Citation
Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN; Investigators of the Cooperative Study of Sickle Cell Disease. Causes of death in sickle cell disease: an autopsy study. Br J Haematol. 2003 Oct;123(2):359-65.
PMID
14531921
Citation
Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003 Aug;25(8):622-8.
PMID
12902915
Firstreceived Results Disposition Date
N/A
Study First Submitted
May 25, 2000
Study First Submitted Qc
May 25, 2000
Study First Posted
May 26, 2000
Last Update Submitted
June 23, 2005
Last Update Submitted Qc
June 23, 2005
Last Update Posted
June 24, 2005
ClinicalTrials.gov processed this data on December 11, 2019
Conditions
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Interventions
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.